PR Newswire
NEW YORK, Nov. 4, 2020
NEW YORK
,
Nov. 4, 2020
/PRNewswire/ — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Reata Pharmaceuticals Inc. (“Reata” or the “Company”) (NASDAQ: RETA) between October 15, 2019 and
August 7, 2020
(the “Class Period”). The lawsuit filed in
the United States
District Court for the Eastern District of
Texas
alleges violations of the Securities Exchange Act of 1934.
If you
purchased Reata securities, and/or would like to discuss your legal rights and options
please visit
Reata Shareholder Lawsuit
or contact
Matthew E. Guarnero
toll free at
(877) 779-1414
or
[email protected]
.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
On
August 10, 2020
, during pre-market hours, Reata issued a press release announcing its second quarter 2020 financial results, wherein it disclosed that the FDA is “not convinced that the MOXIe part 2 results” of the Company’s study assessing omaveleoxolone for the treatment of FA “will support a single study approval without additional evidence that lends persuasiveness to the results,” and that, “in preliminary comments for [a] meeting, the FDA stated that [Defendants] will need to conduct a second pivotal trial that confirms the mFARS results of the MOXIe part 2 study with a similar magnitude of effect.”
On this news, Reata’s stock price fell
$51.79
per share, or 33.16% to close at
$104.41
per share on
August 10, 2020
.
If you wish to serve as lead plaintiff, you must move the Court no later than
December 14, 2020
. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
If you
purchased Reata securities, and/or would like to discuss your legal rights and options
please visit
or contact
Matthew E. Guarnero
toll free at
(877) 779-1414
or
[email protected]
.
Since 1993, Bernstein Liebhard LLP has recovered over
$3.5 billion
for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to
The National Law Journal’s
“Plaintiffs’ Hot List” thirteen times and listed in
The Legal 500
for ten consecutive years.
ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street,
New York, New York
10016, (212) 779-1414. The lawyer responsible for this advertisement in the
State of Connecticut
is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
(877) 779-1414
[email protected]
View original content to download multimedia:
http://www.prnewswire.com/news-releases/reta-loss-alert-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-reata-pharmaceuticals-inc-301166647.html
SOURCE Bernstein Liebhard LLP
